Gangliocytomas of the sellar region: A challenging diagnosis

Cossu, Giulia; Daniel, Roy Thomas; Messerer, Mahmoud

doi:10.1016/j.clineuro.2016.08.002

Cited by 39 publications

(50 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The presence of a neural component does not seem to modify aggressiveness of the tumour or its risk of recurrence after resection 3. No significant difference has been found between pure gangliocytoma and gangliocytoma mixed with pituitary endocrine tumour in terms of patients' characteristics,2 including age of onset, sex ratio, sellar mass syndrome, hormonology, (in)complete surgery.…”

Section: Discussionmentioning

confidence: 91%

“…To date, 129 cases of gangliocytomas have been reported between 1990 and 2016 2 3. Since the exact pathogenesis was unknown, various authors used various ontologies in the previous literature (ganglioneuroma, hamartoma, choristoma) 1.…”

Section: Discussionmentioning

confidence: 99%

“…This rare tumour of unknown prevalence and pathogenesis is now classified in the neuronal and mixed neuroglial tumours section of the 2016 WHO central nervous system tumours classification 1. Its prevalence is very low, less than 130 cases have been reported in the literature 2 3. It may be revealed either by an optic chiasm compression or by hormonal hypersecretion due to associated pituitary adenomas.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Gangliocytoma: outcome of a rare silent pituitary tumour

Donadille¹,

Villa

Gaillard

et al. 2017

BMJ Case Reports

View full text Add to dashboard Cite

The most common finding in front of a pituitary incidentaloma is a silent pituitary adenoma. We describe a 59 years old woman with a pituitary gangliocytoma and her follow-up after 1 year. Hormonal exploration only evidenced partial corticotropic insufficiency. A trans-sphenoidal surgery was performed due to the tumour's suprasellar expansion. Gangliocytoma is a benign tumour of unknown prevalence, belonging to central nervous system tumour with neuronal differentiation, and 129 cases have been reported in the literature. growth hormone (GH), adrenocorticotropic hormone (ACTH) or prolactin secretions have been reported, as these ganglion cell-like mature neurons are usually mixed with secreting pituitary endocrine cells. We report a case with a pure gangliocytoma devoid of symptomatic endocrine secretion, not surrounded by pituitary endocrine tumour cells. Immunochemistry of the tumour was positive for hypothalamic growth hormone releasing hormone (GHRH) and pituitary hormones, such as GH and ACTH. Hence, this immunoexpression was not associated with peripheral hormonal secretions, suggesting biologically inactive hypothalamopituitary hormones.

show abstract

Section: Discussionmentioning

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Gangliocytoma: outcome of a rare silent pituitary tumour

Donadille¹,

Villa

Gaillard

et al. 2017

BMJ Case Reports

View full text Add to dashboard Cite

show abstract

“…Gangliocytomas are very rare benign neuroblastic tumors that originate from ganglion cells, accounting for less than 2% of brain tumors. The majority of these gangliocytomas in the sella are associated with pituitary adenomas, which are the most common benign tumors found in the sella turcica, and account for 10 to 15% of intracranial neoplasms (1,2). The co-existence of these 2 morphologically distinct tumors is known as a collision tumor (3,4).…”

Section: Introductionmentioning

confidence: 99%

“…This is a rare disease entity of which the pathogenesis is not well understood. Collision tumors are more common in females with a mean age of 44 at presentation, most commonly secrete growth hormone (GH) causing acromegaly, and pathologically stain for GH and prolactin (PRL) (1). We present a case of a 44-year-old woman with an incidentally discovered pituitary mass that was found to be a collision tumor containing 2 distinct histologic types: a primarily GH-secreting pituitary adenoma and a gangliocytoma.…”

Section: Introductionmentioning

confidence: 99%

An Incidental Collision Tumor of the Sella Turcica

Levitus

Charitou

2019

AACE Clinical Case Reports

View full text Add to dashboard Cite

Objective: To present a case describing an incidentally discovered pituitary mass that was found to be a collision tumor containing 2 distinct histologic cell types: (1) a growth hormone (GH)-secreting pituitary adenoma, and (2) a gangliocytoma. Methods: Sellar gangliocytomas are very rare benign neuroblastic tumors that originate from the posterior pituitary. The majority are associated with pituitary adenomas. The coexistence of these 2 morphologically distinct tumors is known as a collision tumor, a rare disease entity of which the pathogenesis is not well understood. We present a case of a woman with an incidentally discovered pituitary mass that was found to be a collision tumor. Results: A 44-year-old woman presented with an incidentally discovered pituitary mass and was found to have elevated insulin-like growth factor 1 (IGF-1) levels. The patient underwent endoscopic transsphenoidal excision of the pituitary mass. Histopathology of the tumor revealed a mixed pituitary adenoma that stained for GH and prolactin, and a gangliocytoma. Postoperatively, the patient developed temporary central adrenal insufficiency and permanent diabetes insipidus. Postoperative lab studies revealed a normal IGF-1 level, and a magnetic resonance imaging scan showed no residual or recurrent tumor. Conclusion: While sellar gangliocytoma is a rare lesion, when it is present, a co-existing pituitary adenoma should also be suspected. Further investigation should be done to determine the pathophysiology of these collision tumors, which could be beneficial in guiding diagnosis and treatment. (AACE Clinical Case Rep. 2019;5:e247-e249) Abbreviations: GH = growth hormone; IGF-1 = insulin-like growth factor 1; PRL = prolactin e248 Collision Tumor of the Sella, AACE Clinical Case Rep. 2019;5(No. 4)

show abstract

Hypothalamic Neuroendocrine Neoplasms

Sylvia

Mete

2020

The Spectrum of Neuroendocrine Neoplasia

View full text Add to dashboard Cite

Gangliocytomas of the sellar region: A challenging diagnosis

Cited by 39 publications

References 56 publications

Gangliocytoma: outcome of a rare silent pituitary tumour

Gangliocytoma: outcome of a rare silent pituitary tumour

An Incidental Collision Tumor of the Sella Turcica

Hypothalamic Neuroendocrine Neoplasms

Contact Info

Product

Resources

About